PUBLISHER: Grand View Research | PRODUCT CODE: 1869789
PUBLISHER: Grand View Research | PRODUCT CODE: 1869789
The global controlled release drug delivery market size was estimated at USD 59.8 billion in 2024 and is projected to reach USD 148.6 billion by 2033, growing at a CAGR of 10.7% from 2025 to 2033. Changing prescription patterns of physicians preferring controlled-release drug delivery over conventional systems, owing to the benefits such as high therapeutic efficacy, better patient compliance, and reduced treatment cost, is expected to contribute to the market's growth over the forecast period.
Moreover, being a part of a highly competitive and fragmented market, pharmaceutical companies are proactive with the changing market requirements and continuously invest in developing controlled-release drug delivery systems, thereby significantly driving the demand.
Constantly rising R&D expenditure by pharmaceutical development companies focused on developing efficient therapy for chronic and non-communicable complications such as cancer, diabetes, and hypertension is expected to boost the market growth over the forecast period. For instance, Major pharmaceutical companies such as AbbVie, AstraZeneca, and Merck are implementing controlled drug release systems to enhance the treatment of chronic diseases, cancer, and neurological disorders.
The rising global geriatric and pediatric population is one of the major factors contributing to market growth, largely due to non-adherence to the medicine regimen, which is very common among these age groups. Geriatric populations suffer from compromised physical, mental, and biological functions that affect their medication intake. Also, their bodies cannot tolerate high doses and harsh drug side effects. Thus, the demand for controlled-release drug delivery systems is expected to grow with a steeply rising patient population.
Constantly rising R&D expenditure by pharmaceutical development companies focused on developing efficient therapies for chronic and non-communicable complications such as cancer, diabetes, and hypertension is expected to boost the market growth over the forecast period. For instance, Major pharmaceutical companies such as AbbVie, AstraZeneca, and Merck are implementing controlled drug release systems to enhance the treatment of chronic diseases, cancer, and neurological disorders.
The rising geriatric and pediatric population globally is one of the major factors contributing to market growth, largely due to non-adherence to the medicine regimen, which is very common among these age groups. Geriatric populations suffer from compromised physical, mental, and biological functions that affect their medication intake. Also, their bodies cannot tolerate high doses and the harsh side effects of drugs. Thus, the demand for controlled-release drug delivery systems is expected to grow with a steeply rising patient population.
Controlled release drug delivery significantly reduces dose and dosage frequency, prevents abnormal fluctuations of plasma drug levels, improves efficacy, enhances patient compliance, and achieves a uniform drug effect of the administered drug. Compared to traditional delivery systems, the controlled-release drug delivery systems achieve a prolonged therapeutic effect, delivering the drug at the target site at a pre-determined rate and with predictable drug release kinetics. Thus, with several added benefits offered by the controlled release delivery system, their adoption is expected to increase notably over the forecast period.
Global Controlled Release Drug Delivery Market Report Segmentation
This report forecasts country-level revenue growth and analyzes the latest industry trends and opportunities in each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the global controlled release drug delivery market report based on technology, release mechanism, and region: